Journal of Autism and Developmental Disorders

, Volume 46, Issue 4, pp 1455–1463 | Cite as

Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome

  • Emeline Crutcher
  • May Ali
  • John Harrison
  • Judit Sovago
  • Baltazar Gomez-Mancilla
  • Christian P. Schaaf
Original Paper


15q13.3 microdeletion syndrome causes a spectrum of cognitive disorders, including intellectual disability and autism. We aimed to determine if any or all of three cognitive testing systems (the KiTAP, CogState, and Stanford–Binet) are suitable for assessment of cognitive function in affected individuals. These three tests were administered to ten individuals with 15q13.3 microdeletion syndrome (14–18 years of age), and the results were analyzed to determine feasibility of use, potential for improvement, and internal consistency. It was determined that the KiTAP, CogState, and Stanford–Binet are valid tests of cognitive function in 15q13.3 microdeletion patients. Therefore, these tests may be considered for use as objective outcome measures in future clinical trials, assessing change in cognitive function over a period of pharmacological treatment.


Neuropsychiatric disease Autism Intellectual disability Cognitive tests Cognitive function 



We are indebted to the patients and their families for their willingness to participate in our study. This work was supported in part by the Doris Duke Charitable Foundation Grant # 2011034 and in part as an Investigator Initiated Research Protocol by Novartis Pharmaceuticals Corporation. The project was supported in part by IDDRC Grant Number 1U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Cores: Tissue culture core, translational core. CS is generously supported by the Joan and Stanford Alexander Family.


John Harrison has previously received consultancy payments from the Novartis Pharmaceutical Corporation.

Author Contributions

All listed authors have made contributions to the work discussed in this article. All authors have reviewed the completed manuscript, and given feedback, resulting in the final submitted product. Specific contributions of each author are listed below. Emeline Crutcher: Analyzed data collected during the study and wrote the manuscript discussing the results. May Ali: Clinical research coordinator—established and maintained contact with the patients’ families throughout the study to coordinate travel arrangements and clinical visits for administration of each test. John Harrison: Assisted with study design, and provided valuable input throughout the data analysis process. Judit Sovago: Assisted with study design. Baltazar Gomez-Mancilla: Assisted with study design. Christian P. Schaaf: Primary investigator for this study. Planned, designed, and conducted the study.


  1. Aman, M. G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K. D., et al. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9(1), 36–47.PubMedPubMedCentralGoogle Scholar
  2. Freedman, R. (2014). α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annual Review of Medicine, 65(September 2013), 245–261.CrossRefPubMedGoogle Scholar
  3. Gillentine, M. A., & Schaaf, C. P. (2015). The human clinical phenotypes of altered CHRNA7 copy number. Biochemical Pharmacology. doi: 10.1016/j.bcp.2015.06.012.PubMedGoogle Scholar
  4. Grondhuis, S., & Mulick, J. (2013). Comparison of the Leiter International Performance Scale-Revised and the Stanford–Binet Intelligence Scales, 5th Edition, in children with autism spectrum disorders. American Journal on Intellectual and Developmental Disabilities, 118(1), 44–54.CrossRefPubMedGoogle Scholar
  5. Hellwig-Brida, S., Daseking, M., Keller, F., Petermann, F., & Goldbeck, L. (2011). Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(3), 245–253.CrossRefPubMedGoogle Scholar
  6. Jucaite, A., Öhd, J., Potter, A. S., Jaeger, J., Karlsson, P., Hannesdottir, K., et al. (2014). A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology, 231(6), 1251–1265.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Kaufmann, L., Zieren, N., Zotter, S., Karall, D., Scholl-Bürgi, S., Haberlandt, E., et al. (2010). Predictive validity of attentional functions in differentiating children with and without ADHD: A componential analysis. Developmental Medicine and Child Neurology, 52(4), 371–378.CrossRefPubMedGoogle Scholar
  8. Knox, A., Schneider, A., Abucayan, F., Hervey, C., Tran, C., Hessl, D., et al. (2012). Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS). Journal of Neurodevelopmental Disorders, 4(1), 2. doi: 10.1186/1866-1955-4-2.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Lowther, C., Costain, G., Stavropoulos, D. J., Melvin, R., Silversides, C. K., Andrade, D. M., et al. (2014). Delineating the 15q13.3 microdeletion phenotype: A case series and comprehensive review of the literature. Genetics in Medicine, 17(2), 149–157.CrossRefPubMedPubMedCentralGoogle Scholar
  10. MedFriendly: Standard Score to Percentile Conversion. (n.d.). Retrieved from Accessed 2 June 2015.
  11. Mollica, C. M., Maruff, P., & Vance, A. (2004). Development of a statistical approach to classifying treatment response in individual children with ADHD. Human Psychopharmacology, 19(7), 445–456.CrossRefPubMedGoogle Scholar
  12. Ozonoff, S., Goodlin-Jones, B. L., & Solomon, M. (2005). Evidence-based assessment of autism spectrum disorders in children and adolescents. Journal of Clinical Child and Adolescent Psychology, 34(3), 523–540.CrossRefPubMedGoogle Scholar
  13. Rothmann, K., Hillmer, J., & Hosser, D. (2014). Evaluation of the Musical Concentration Training with Pepe (MusiKo mit Pepe) for children with attention deficits. Zeitschrift für Kinder-und Jugendpsychiatrie und Psychotherapie, 42(5), 325–335.CrossRefPubMedGoogle Scholar
  14. Sandler, A. (2005). Placebo effects in developmental disabilities: Implications for research and practice. Mental Retardation and Developmental Disabilities Research Reviews, 11(2), 164–170.CrossRefPubMedGoogle Scholar
  15. Schaaf, C. P. (2014). Nicotinic acetylcholine receptors in human genetic disease. Genetics in Medicine, 16(9), 649–656.CrossRefPubMedGoogle Scholar
  16. Silverman, W., Miezejeski, C., Ryan, R., Zigman, W., Krinsky-McHale, S., & Urv, T. (2010). Stanford–Binet and WAIS IQ differences and their implications for adults with intellectual disability (aka mental retardation). Intelligence, 38(2), 242–248.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Tropeano, M., Andrieux, J., Vassos, E., & Collier, D. A. (2014). Clinical utility gene card for: 15q13.3 microdeletion syndrome. European Journal of Human Genetics, 22(11), 1338.CrossRefPubMedCentralGoogle Scholar
  18. Yamashita, Y., Mukasa, A., Anai, C., Honda, Y., Kunisaki, C., Koutaki, J., et al. (2011). Summer treatment program for children with attention deficit hyperactivity disorder: Japanese experience in 5 years. Brain and Development, 33(3), 260–267.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Translational Biology and Molecular MedicineBaylor College of MedicineHoustonUSA
  2. 2.Department of Molecular and Human GeneticsBaylor College of MedicineHoustonUSA
  3. 3.Jan and Dan Duncan Neurological Research Institute, Texas Children’s HospitalHoustonUSA
  4. 4.Alzheimer CenterVU Medical CenterAmsterdamThe Netherlands
  5. 5.Novartis Pharmaceutical CorporationBaselSwitzerland
  6. 6.McGill UniversityMontrealCanada

Personalised recommendations